Pathology-guided treatment of rectal cancer
| ISRCTN | ISRCTN28785842 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN28785842 |
| ClinicalTrials.gov (NCT) | NCT00003422 |
| Protocol serial number | CR07 |
| Sponsor | Medical Research Council (MRC) (UK) |
| Funder | Medical Research Council (MRC) (UK) |
- Submission date
- 06/04/2000
- Registration date
- 06/04/2000
- Last edited
- 17/10/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr David Sebag-Montefiore
Scientific
Scientific
Leeds Cancer Centre
Cookridge Hospital
Hospital Lane
Leeds
LS16 6QB
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | Pathology-guided treatment of rectal cancer: a randomised controlled trial |
| Study objectives | In inoperable rectal cancer: are local recurrence-free survival rates and quality of life optimised by giving all patients short course pre-operative radiotherapy, or is it a preferable option to give post-operative chemoradiotherapy only to those at high risk of recurrence (i.e. with involved margins following surgery)? |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Rectal cancer |
| Intervention | 1. One group receives a short course pre-operative radiotherapy followed by surgery 2. The other group receives surgery followed by postoperative chemo-radiotherapy |
| Intervention type | Other |
| Primary outcome measure(s) |
Local recurrence (as defined using an algorithm designed for the trial). |
| Key secondary outcome measure(s) |
1. Local recurrence-free survival |
| Completion date | 05/08/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 1350 |
| Key inclusion criteria | 1. Histologically confirmed adenocarcinoma of the rectum 2. Considered potentially operable 3. No evidence of metastases 4. Patient considered fit to receive either arm of the trial 5. No concurrent uncontrolled medical illness 6. No previous or current malignant disease likely to interfere with treatment or comparisons 7. Informed consent obtained |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/02/1998 |
| Date of final enrolment | 05/08/2005 |
Locations
Countries of recruitment
- United Kingdom
- England
- Canada
Study participating centre
Leeds Cancer Centre
Leeds
LS16 6QB
United Kingdom
LS16 6QB
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Initial results: | 07/03/2009 | Yes | No | |
| Results article | Prospective study results: | 07/03/2009 | Yes | No | |
| Plain English results | No | Yes | |||
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
17/10/2018: Cancer Research UK lay results summary link added to Results (plain English)